Table 3.
Adjusted analyses for triglycerides, HDL-C, and total cholesterol : HDL-C ratio.**
| Covariate | Mean difference in triglycerides mmol/L (95% CI) | Mean difference in HDL-C mmol/L (95% CI) | Mean difference in total cholesterol : HDL-C ratio (95% CI) |
|---|---|---|---|
| Regimen | |||
| NRTIs (+TDF) + NVP | Reference | Reference | Reference |
| NRTIs (+TDF) + EFV | 0.17 (−0.19 to 0.53) | 0.01 (−0.06 to 0.08) | 0.16 (−0.16 to 0.47) |
| NRTIs + NVP | 0.58 (0.29 to 0.87) | 0.15 (0.08 to 0.21) | 0.13 (−0.12 to 0.39) |
| NRTIs + EFV | 0.64 (0.34 to 0.95) | 0.09 (0.03 to 0.16) | 0.29 (0.01 to 0.56) |
| NRTIs (+TDF) + PI(+ATV) | 0.15 (−0.22 to 0.52) | −0.03 (−0.11 to 0.05) | 0.29 (−0.04 to 0.62) |
| NRTIs (+TDF) + PI | 1.06 (0.73 to 1.38) | −0.02 (−0.09 to 0.05) | 0.66 (0.37 to 0.95) |
| NRTIs + PI(+ATV) | 0.57 (0.24 to 0.90) | 0.03 (−0.05 to 0.10) | 0.34 (0.02 to 0.65) |
| NRTIs + PI | 1.13 (0.83 to 1.43) | 0.01 (−0.06 to 0.07) | 0.75 (0.47 to 1.03) |
| P | <0.001 | <0.001 | <0.001 |
| Cohort | |||
| AHOD | Reference | Reference | Reference |
| TAHOD | 0.33 (0.11 to 0.55) | 0.04 (−0.01 to 0.09) | −0.16 (−0.40 to 0.08) |
| P | 0.003 | 0.146 | 0.187 |
Table shows independent effects of regimen and cohort variables in adjusted analyses. Since the interaction term between these variables was not significant, it was not included in the models. Figure 1 shows the interaction between regimen and cohort variables.
**Multivariable models were a priori adjusted for time on given regimen, Hepatitis B and/or C coinfections, age, gender, HIV RNA viral load copies/mL, CD4+ T-cell count, BMI, cumulative exposure to cART at the start of regimen, and HIV exposure category. AHOD: Australian HIV Observational Database, ATV: Atazanavir; cART: combinational antiretroviral therapy; CI: confidence interval; EFV: Efavirenz; HBV: Hepatitis B co-infection; HCV: Hepatitis C co-infection; IDU: Intravenous drug user; NNRTI: nonnucleoside reverse transcriptase inhibitors; NRTI: nucleoside reverse transcriptase inhibitors, NVP: nevirapine, PI: protease inhibitor, TAHOD: TREAT Asia HIV Observational Database; TDF: Tenofovir. Key. NRTIs are TDF based (NRTIs + TDF) or not (NRTIs) and PI as ATV based (PI + ATV) or not (PI).